Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIPHER: Carbon Ion vs Conventional Photon Radiation for Unresectable Pancreatic Cancer
jRCTs032180179Phase 3Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: overall survival. Started Aug 2017; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on jRCTs032180179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs032180179.